Tradestie Institutional Equity Comparison Engine
MBIO vs SRZN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (2โ1 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Momentum & Technical, Options & Structure while MBIO counters with relative strength in Growth & Margin. Fundamentally, MBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
MBIO N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner
MBIO
Op Margin 0.0% vs -485.4% ยท YoY +0.0% vs +408.6%
Momentum & Technical Winner
SRZN
1Y -68.4% vs +166.7% ยท 52W Pos 3% vs 79%
Options & Structure Winner
SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (5th %ile IV)
MBIO
NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap
$3.2M
1M Return
+3.22%
1Y Return
-68.44%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 40.0
Fund 49.0
Flow 50.0
Mom 70.0
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap
$602.5M
1M Return
+37.88%
1Y Return
+166.67%
Forward P/E
N/M
Unified AI Score
33.2 / 100
SELL
Tech 50.0
Fund 34.0
Flow 65.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MBIO -68.44%
SRZN +166.67%
Spread: +216.65 pp (SRZN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MBIO TTM Op. Margin: 0.0%
SRZN TTM Op. Margin: -485.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs SRZN. Trailing 12-month operating profitability (MBIO 0.0% vs SRZN -485.4%) and valuation multiples (MBIO N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MBIO | SRZN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.2M | $602.5M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +408.6% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | 0.0% | -485.4% | Higher Margin | MBIO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -43.1% | -62.8% | Higher ROE | MBIO |
| 52-Week Range Position Momentum | 3% ($0โ$1) | 79% ($12โ$38) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 0.68ฮฒ ยท 87% Vol | 1.21ฮฒ ยท 62% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 33.2 / 100 (SELL) | Higher Composite | MBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MBIO vs SRZN Buy Guide
MBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SRZN
CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MBIO nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.